Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy-Reference-Cited by-同舟云学术

Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy

Published:2018-10-15 Issue:1 Volume:83 Page:53-60
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Nersting Jacob^ORCID, ,Nielsen Stine Nygaard,Grell Kathrine,Paerregaard Maria,Abrahamsson Jonas,Lund Bendik,Jonsson Olafur Gisli,Pruunsild Kaie,Vaitkeviciene Goda,Kanerva Jukka^ORCID,Schmiegelow Kjeld^ORCID

Funder

Børnecancerfonden

Kræftens Bekæmpelse

Barncancerfonden

Nordic Cancer union

Ingeniør Otto Christensens Fond

Rigshospitalet

Novo Nordisk Fonden

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3704-7/fulltext.html

Reference20 articles.

1. Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J (2014) Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol 36(7):503–517. https://doi.org/10.1097/MPH.0000000000000206

2. Karran P, Attard N (2008) Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 8(1):24–36. https://doi.org/10.1038/nrc2292

3. Nielsen SN, Frandsen TL, Nersting J, Hjalgrim LL, Schmiegelow K (2015) Pharmacokinetics of 6-thioguanine and 6-mercaptopurine combination maintenance therapy of childhood ALL: hypothesis and case report. J Pediatr Hematol Oncol 37(3):e206–e209. https://doi.org/10.1097/MPH.0000000000000246

4. Schmiegelow K (2009) Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 146(5):489–503. https://doi.org/10.1111/j.1365-2141.2009.07765.x

5. Nielsen SN, Grell K, Nersting J, Frandsen TL, Hjalgrim LL, Schmiegelow K (2016) Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol 78(5):983–994. https://doi.org/10.1007/s00280-016-3151-2

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic polymorphisms and their association with methotrexate polyglutamates during maintenance treatment in Korean children and young adults with acute lymphoblastic leukemia;European Journal of Pharmaceutical Sciences;2024-11

2. Modalités pratiques de prise en charge en cours de traitement d’entretien des leucémies aiguës lymphoblastiques pédiatriques : recommandations du Comité leucémies de la Société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent (SFCE);Bulletin du Cancer;2022-11

3. A Retrospective Cohort Study of the Efficacy, Safety, and Clinical Value of 6-TG versus 6-MP Maintenance Therapy in Children with Acute Lymphoblastic Leukemia;BioMed Research International;2022-08-21

4. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations;Leukemia;2022-06-02

5. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0–45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol;BMC Cancer;2022-05-02